Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 10/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13327800 | 0.91 | CHRM4 (0.37) | ITGALGPR119CHRM4POLB | |
| SCHEMBL13304568 | 0.91 | HDAC6 (0.47) | CHRM4 | |
| SCHEMBL13304550 | 0.89 | GPR119 (0.41) | GPR119CHRM4SIGMAR1 | |
| SCHEMBL13304530 | 0.87 | ITGAL (0.41) | ITGALGPR119CHRM4SIGMAR1CHRM2 | |
| SCHEMBL8249401 | 0.83 | GPR119 (0.37) | GPR119CHRM4SIGMAR1PRKAA2 | |
| SCHEMBL13304552 | 0.82 | CHRM4 (0.41) | GPR119CHRM4 | |
| SCHEMBL13328356 | 0.82 | HDAC6 (0.47) | — | |
| SCHEMBL13304563 | 0.79 | HDAC6 (0.48) | PRKAA2 | |
| SCHEMBL13304564 | 0.79 | HDAC6 (0.54) | — | |
| SCHEMBL13304529 | 0.79 | ELANE (0.41) | GPR119PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160321-A1 | IMIDAZOLINONE AND HYDANTOINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160321-A1 | IMIDAZOLINONE AND HYDANTOINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC3 | ITGAL 3662/4885GPR119 1042/4885CHRM4 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.